This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. Read More
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer. Read More
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
This study enrolls parents whose child may need elective surgery. This study surveys parents who are bringing their child to a UBMD surgical clinic about their concerns about potentially having their child have elective surgery. Read More
Parent or guardian of pediatric otolaryngology patients at UBMD, who are children aged 0 to 18 years
Participant must be at least 18 years old
Able to read English at grade 8 level or above
This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion. Read More
Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.
This study enrolls adults who have had heart failure or heart attack or who are generally healthy. The purpose of this study is to learn more about how these types of cardiovascular issues happen at a biological level. We will do that by looking at the immune cells in the blood. Read More
Adults ages 18+
Generally healthy OR are presenting to the hospital with heart failure or acute myocardial infarction (heart attack).
This study enrolls children who have a mitochondrial disease. The purpose of this research is to learn more about mitochondrial diseases, including their genetic causes and the types of medical problems associated with them. Read More
Must have a known or suspected pathogenic mutation in mitochondrial DNA or a mitochondrial related gene in the chromosomal DNA.
This study enrolls children and young adults with Juvenile idiopathic arthritis. The purpose of this study is to understand the relationship between biochemical and genetic markers and the way a person's body responds to drugs. We also want to learn more about the development of lung disease in people with systemic juvenile idiopathic arthritis. Read More
-Children and young adults ages 1-21.
-Diagnosed with Juvenile idiopathic arthritis (sJIA) and has lung involvement.
This study enrolls medical students. The goal of the study is to learn if measurements we take through brain imaging, video, and eye tracking can show the difference between experts and novices when they do emergency medical tasks. Read More
-Adults ages 18+.
-Are a medical student practicing physician with experience in emergency medicine or prolonged field care skills OR do not have experience with emergency medicine or prolonged field care tasks.
-Are able to stand continuously for 20 minutes.